iodine-124-labeled enfortumab vedotin

124I-EV is an iodine-124-labeled imaging probe developed by Peking University Cancer Hospital & Institute for PET/CT imaging of Nectin-4-expressing solid tumors. The probe utilizes enfortumab vedotin (EV), an FDA-approved antibody-drug conjugate targeting Nectin-4, which is radiolabeled with the positron emitter iodine-124 (124I). Nectin-4 is a cell adhesion molecule frequently overexpressed in various epithelial cancers, including urothelial carcinoma and triple-negative breast cancer. By enabling non-invasive visualization of Nectin-4 expression, 124I-EV serves as a companion diagnostic tool to identify patients likely to benefit from Nectin-4-targeted therapies and to monitor their treatment response.

Other names

124I-enfortumab vedotiniodine-124-labeled enfortumab vedotiniodine124-labeled enfortumab vedotiniodine 124-labeled enfortumab vedotin